En résumé, le sang périphérique provenant de donneurs sains a été la source optimale pour les
l’expansion des cellules NK. L’administration de G-CSF aux patients diminue la population et
la fonctionnalité des cellules NK CD56
brightCD16
+et favorise le développement d’une
population présentant une absence ou une difficulté d’acquisition du CD16, responsable de la
médiation du mécanisme de cytotoxicité dépendante des anticorps. Surmonter cette altération
de la capacité lymphoïde peut être important pour faciliter l’immunothérapie
post-111
transplantation. De plus, nous avons observé une surexpression de la plupart des cinq
récepteurs après 14 jours de culture, et l’expression de KIR2DL1, KIR2DL3, KIR2DL5 et
CD137 était significativement différente entre les trois origines des cellules NK.
112
Bibliographie
1. Abdel-Wahab O, Levine RL. Mutations in epigenetic modifiers in the pathogenesis and
therapy of acute myeloid leukemia. Blood 2013; 121:3563-3572.
2. Abea Y, Mutob M, Nieda M, et al. Clinical and immunological evaluation of
zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma.
Experimental Hematology 2009; 37:956-968.
3. Baba J, Watanabe S, Saida Y, Tanaka T, Miyabayashi T, Koshio J, et al. Depletion of
radio-resistant regulatory T cells enhances antitumor immunity duringrecovery from
lymphopenia. Blood 2012; 120:2417-2427.
4. Bachanova V, Cooley S, Defor TE, Verneris MR, Zhang B, McKenna DH, et al.
Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved
using IL-2 diphtheria toxin fusion protein. Blood 2014; 123:3855-3863.
5. Bacher U, Haferlach T, Fehse B, Schnittger S, Kroger N. Minimal residual disease
diagnostics and chimerism in the post-transplant period in acute myeloid leukemia.
Scientific World Journal 2011; 11:310-319.
6. Bacher U, Talano JA, Bishop MR. Monitoring and prevention of relapse after allogeneic
hematopoietic cell transplantation for myeloid malignancies. Biol Blood Marrow
Transplant. 2012; 18:S62-S73.
7. Bader P, Niethammer D, Willasch A, Kreyenberg H, Klingebiel T. How and when should
we monitor chimerism after allogeneic stem cell transplantation? Bone Marrow
Transplant. 2005; 35:107-119.
8. Bader P, Willasch A, Klingebiel T. Monitoring of post-transplant remission of childhood
malignancies: is there a standard. Bone Marrow Transplant. 2008; 42(Suppl. 2):S31-S34.
113
human and mouse NK cells and impairs NK-cell reactivity against huamn acute myeloid
leukemia cells. Blood 2010; 115:3058-3069.
10. Baggio L, Laureano ÁM, da Rocha Silla LM, Lee DA. Natural killer cell adoptive
immunotherapy: coming of age. Clin. Immunol. 2016; http://dx.doi.org/10.1016/
j.clim.2016.02.003.
11. Baier C, Fino A, Sanchez C, Farnault L, Rihet P, Kahn-Perles B, et al. Natural killer cells
modulation in hematological malignancies. Front. Immunol. 2013; 4:459.
12. Bar M, Sandmaier BM, Inamoto Y, et al. Donor lymphocyte infusion for relapsed
hematological malignancies after allogeneic hematopoietic cell transplantation:
prognostic relevance of the initial CD3+ T cell dose. Biol Blood Marrow Transplant.
2013; 19:949-957.
13. Baron F, Baker JE, Strob R, Gooley TA, Sandmaier BM, Mickael B, et al. Kinetics of
engraftment in patients with hematological malignancies given allogeneic hematopoietic
cell transplantation after non-myeloablative conditioning. Blood 2004; 104:2254-2262.
14. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell
transplantation following nonmyeloablative conditioning. Leukaemia 2006;
20:1690-1700.
15. Barrett AJ. Understanding and harnessing the graft-versus-leukaemia effect. Br J
Haematol. 2008; 142:877-888.
16. Becknell B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural
killer cells. Adv. Immunol. 2005; 86:209-239.
17. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute
leukaemias. French-American-British (FAB) cooperative group. Br J Haematol. 1976; 33:
451-458.
114
18. Berg M, Childs R. Ex-vivo expansion of NK cells: what is the priority-high yield or high
purity? Cytotherapy. 2010; 12:969-970.
19. Berg M, Lundqvist A, Betters D, Childs RW. In vitro expanded NK cells have increased
natural cytotoxity receptors, TRAIL and NKG2D expression, and superior tumor
cytotoxicity compared to short-term IL-2-activated NK cells [abstract]. Blood (ASH
Annual Meeting Abstracts). 2009; 114:463.
20. Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, et al. Clinical-grade ex
vivo-expanded human natural killer cells up-regulate activating receptors and death
receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy.
2009; 11:341-355.
21. Berrien-Elliott MM, Wagner JA, Fehniger TA. Human cytokine-induced memory-like
natural killer cells. J. Innate Immun. 2015; 7:563-571.
22. Beziat V, Duffy D, Quoc SN, et al. CD56
brightCD16
+NK cells: a functional intermediate
stage of NK cell differentiation. The journal of immunology. 2011; 186: 6753-6761.
23. Blom B, Spits H. Development of human lymphoid cells. Annu Rev Immunol 2006; 24:
287-320.
24. Boissel L, Tuncer HH, Betancur M, Wolfberg A, Klingemann H. Umbilical cord
mesenchymal stem cells increase expansion of cord blood natural killer cells. Biol. Blood
Marrow Transplant. 2008; 14:1031-1038.
25. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that
originates from a primitive hematopoietic cell. Nat. Med. 1997; 3:730-737.
26. Bonneville M, O’Brien RL, Born WK. γδ T cell effector functions: a blend of innate
programming and acquired plasticity. Nat. Rev. Immunol. 2010; 10:467- 478.
115